GAM
KERX

Gotham Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Gotham Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-36,288
Closed -$258K – 1118
2017
Q3 		$258K Sell
36,288
-19,351
-35% -$139K ﹤0.01% 829
2017
Q2 		$402K Buy
+55,639
New +$348K 0.01% 784
2017
Q1 		– Sell
-76,726
Closed -$450K – 1158
2016
Q4 		$450K Buy
+76,726
New +$419K 0.01% 743
2016
Q3 		– Sell
-77,976
Closed -$516K – 1108
2016
Q2 		$516K Buy
77,976
+52,519
+206% +$294K 0.01% 719
2016
Q1 		$119K Buy
+25,457
New +$102K ﹤0.01% 933

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Gotham Asset Management's KERX Position: Q4 2017 in Review

Gotham Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 36,288 shares — an estimated $258K sold.

Gotham Asset Management first reported a position in KERX in Q1 2016 and held it in 5 quarters. The position peaked at $516K in Q2 2016. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • Gotham Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Gotham Asset Management sold 36,288 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $258K.
  • Gotham Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2016 and held it in 5 quarters.
  • Gotham Asset Management's Keryx Biopharmaceuticals Inc position peaked at $516K in Q2 2016.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Gotham Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.